Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2026 | Ropeginterferon may redefine frontline and second-line treatment in ET

Lucia Masarova • 13 Jun 2026
EHA 2026
Essential Thrombocythemia Myeloproliferative Neoplasm Anagrelide Ropeginterferon alfa-2b
EXCEED-ET

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how ropeginterferon alfa-2b could reshape the treatment landscape for essential thrombocythemia (ET). Dr Masarova reviews data supporting the use of ropeginterferon in both frontline and second-line settings, comments on patient selection and safety considerations, and highlights the growing importance of molecular responses and disease modification in ET management. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lucia Masarova

SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
1:35
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova • 13 Jun 2026
Novel targeted and anti-inflammatory strategies advance MPN treatment landscape
2:30
Novel targeted and anti-inflammatory strategies advance MPN treatment landscape
Lucia Masarova • 13 Jun 2026
Promising combination strategies being explored in myelofibrosis
3:27
Promising combination strategies being explored in myelofibrosis
Lucia Masarova • 22 Aug 2025
The most promising emerging therapies and developments in PV and ET
1:56
The most promising emerging therapies and developments in PV and ET
Lucia Masarova • 22 Aug 2025

Related Videos

SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
1:35
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova • 13 Jun 2026
Novel targeted and anti-inflammatory strategies advance MPN treatment landscape
2:30
Novel targeted and anti-inflammatory strategies advance MPN treatment landscape
Lucia Masarova • 13 Jun 2026
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
2:28
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
Ruben Mesa • 12 Jun 2026
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
The content of VJHemOnc is intended for healthcare professionals